9 Matching Annotations
  1. Apr 2022
  2. www.sciencedirect.com www.sciencedirect.com
    Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
    1
    1. Marlene_Wulf 27 Apr 2022

      Payne, R. P., Longet, S., Austin, J. A., Skelly, D. T., Dejnirattisai, W., Adele, S., Meardon, N., Faustini, S., Al-Taei, S., Moore, S. C., Tipton, T., Hering, L. M., Angyal, A., Brown, R., Nicols, A. R., Gillson, N., Dobson, S. L., Amini, A., Supasa, P., … Zawia, A. A. T. (2021). Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell, 184(23), 5699-5714.e11. https://doi.org/10.1016/j.cell.2021.10.011

      is:article lang:en COVID-19 immunogenicity mRNA Pfizer-BioNTech vaccine dosing interval antibody UK graphic T cell B cell
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S0092867421012216
  3. Feb 2022
  4. www.sciencedirect.com www.sciencedirect.com
    SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses
    1
    1. lucyparfitt16 10 Feb 2022

      Chatterjee, D., Tauzin, A., Marchitto, L., Gong, S. Y., Boutin, M., Bourassa, C., Beaudoin-Bussières, G., Bo, Y., Ding, S., Laumaea, A., Vézina, D., Perreault, J., Gokool, L., Morrisseau, C., Arlotto, P., Fournier, É., Guilbault, A., Delisle, B., Levade, I., … Finzi, A. (2022). SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses. Cell Reports, 0(0). https://doi.org/10.1016/j.celrep.2022.110429

      is:report is:article lang:en COVID-19 Omicron vaccine vaccine dose interval neutralization response mutation vaccine efficacy infection-induced immunity spike glycoproteins delayed mRNA vaccine regimen variants of concern humoral response
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S221112472200153X
  5. www.nature.com www.nature.com
    Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses
    1
    1. lucyparfitt16 04 Feb 2022

      Hall, V. G., Ferreira, V. H., Wood, H., Ierullo, M., Majchrzak-Kita, B., Manguiat, K., Robinson, A., Kulasingam, V., Humar, A., & Kumar, D. (2022). Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nature Immunology, 1–6. https://doi.org/10.1038/s41590-021-01126-6

      is:article lang:en COVID-19 vaccine T cell response delayed dosing interval immunization strategy humoral immunity healthcare worker dose variant
    Visit annotations in context

    Tags

    Annotators

    URL

    nature.com/articles/s41590-021-01126-6
  6. Dec 2021
  7. www.bmj.com www.bmj.com
    Covid-19 vaccines, immunity, and boosters
    1
    1. lucyparfitt16 21 Dec 2021

      Richterman, A., Scott, J., & Cevik, M. (2021). Covid-19 vaccines, immunity, and boosters. BMJ, 375, n3105. https://doi.org/10.1136/bmj.n3105

      is:article lang:en COVID-19 vaccine immunity booster dose protection effectiveness research risk vaccine interval variant delta hospitalization waning immunity Omicron antibody response
    Visit annotations in context

    Tags

    Annotators

    URL

    bmj.com/content/375/bmj.n3105
  8. Sep 2021
  9. twitter.com twitter.com
    John Burn-Murdoch on Twitter
    1
    1. XanaButt 03 Sep 2021

      John Burn-Murdoch. (2021, August 23). NEW: in the last couple of weeks there have a lot of new studies out assessing vaccine efficacy, many of which have touched on the question of waning immunity. Unsurprisingly, these have prompted a lot of questions. Time for a thread to summarise what we do and don’t know: [Tweet]. @jburnmurdoch. https://twitter.com/jburnmurdoch/status/1429878189011111936

      is:twitter lang:en COVID-19 vaccine vaccine efficacy waning risk exposure immunology Israel hospitalization age T cell B cell antibody interval
    Visit annotations in context

    Tags

    Annotators

    URL

    twitter.com/jburnmurdoch/status/1429878189011111936
  10. Jul 2021
  11. twitter.com twitter.com
    Thushan de Silva on Twitter
    1
    1. jasminehollingworth 29 Jul 2021

      Thushan de Silva on Twitter. (n.d.). Twitter. Retrieved 29 July 2021, from https://twitter.com/Thushan_deSilva/status/1418511974435115011

      lang:en is:tweet COVID-19 immune immune response vaccine vaccination dose interval UK antibody T cell Pfizer alpha variant delta infected pattern
    Visit annotations in context

    Tags

    Annotators

    URL

    twitter.com/Thushan_deSilva/status/1418511974435115011
  12. May 2021
  13. www.newscientist.com www.newscientist.com
    US refuses to extend time between coronavirus vaccine doses
    1
    1. emilybiggs 03 May 2021

      Lawton, G. (n.d.). US refuses to extend time between coronavirus vaccine doses. New Scientist. Retrieved March 24, 2021, from https://www.newscientist.com/article/mg24933263-700-us-refuses-to-extend-time-between-coronavirus-vaccine-doses/

      is:news lang:en COVID-19 vaccine USA dose delay UK Canada Germany interval
    Visit annotations in context

    Tags

    Annotators

    URL

    newscientist.com/article/mg24933263-700-us-refuses-to-extend-time-between-coronavirus-vaccine-doses/
  14. Apr 2021
  15. www.nature.com www.nature.com
    Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination
    1
    1. sophia.sterckx 10 Apr 2021

      Cobey, Sarah, Daniel B. Larremore, Yonatan H. Grad, and Marc Lipsitch. ‘Concerns about SARS-CoV-2 Evolution Should Not Hold Back Efforts to Expand Vaccination’. Nature Reviews Immunology, 1 April 2021, 1–6. https://doi.org/10.1038/s41577-021-00544-9.

      is:article lang:en COVID-19 vaccination expanding vaccination limited supply doses interval between doses disease mortality partial immunity variants vaccine effectiveness naturally induced immunity
    Visit annotations in context

    Tags

    Annotators

    URL

    nature.com/articles/s41577-021-00544-9
  16. Mar 2021
  17. Local file Local file
    Untitled document
    1
    1. alexandra.p 19 Mar 2021

      Smith, P. (2021). Interim recommendations for use of the AZD1222 (ChAdOx1-S (recombinant)) vaccine against COVID-19 developed by Oxford University and AstraZeneca. WHO.

      is:pdf lang:en COVID-19 vaccine Oxford AstraZeneca interim guidance WHO SAGE recommendation clinical trial efficacy interdose interval

    Tags

    Annotators